Boan Biology: The company's two types of monoclonal antibodies, Deshumab injection, have been accepted for market application in the UK.

On the afternoon of November 7th, Biogen announced on the Hong Kong Stock Exchange that the company's UK marketing authorization applications for Denosumab Injection 60mg in the orthopedic field and Denosumab Injection 120mg in the oncology field, which were independently developed by the company, have been accepted by the Medicines and Healthcare products Regulatory Agency in the UK.